Valaciclovir
Clinical data | |
---|---|
Trade names | Valtrex, Zelitrex, others |
Other names | valacyclovir, valacyclovir hydrochloride (USAN US) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a695010 |
License data |
|
Pregnancy category |
|
Antiviral | |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 55% |
Protein binding | 13–18% |
Metabolism | Liver (to aciclovir) |
Elimination half-life | <30 minutes (valaciclovir); 2.5–3.6 hours (aciclovir) |
Excretion | Kidney 40–50% (aciclovir), faecal 47% (aciclovir) |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Valaciclovir, also spelled valacyclovir, is an
Common side effects include
Valaciclovir was patented in 1987 and came into medical use in 1995.
Medical uses
Valaciclovir is used for the treatment of HSV and VZV infections, including:[9]
- Oral and genital prevention)
- Reduction of HSV and VZV transmission from people with recurrent infection to uninfected individuals
- Herpes zoster (shingles): the typical dosage for treatment of herpes is 1,000 mg orally three times a day for seven consecutive days.[10]
- Prevention of cytomegalovirus following organ transplantation
- Prevention of herpesviruses in immunocompromised people (such as those undergoing cancer chemotherapy)[11]
- Chickenpox in children (ages 2–18)[1]
It has shown promise as a treatment for infectious mononucleosis[12][13][14] and is preventively administered in suspected cases of herpes B virus exposure.[15]
Bell's palsy does not seem to benefit from using valaciclovir as its only treatment.[16][17]
Adverse effects
Common
Pharmacology
Valaciclovir is a prodrug, an
Mechanism of action
Aciclo-GTP, the active triphosphate metabolite of aciclovir, is a very potent inhibitor of
Aciclovir is active against most species in the
- Herpes simplex virus type I (HSV-1)
- Herpes simplex virus type II (HSV-2)
- Varicella zoster virus (VZV)
- Epstein–Barr virus (EBV)
- Cytomegalovirus (CMV)
The drug is predominantly active against HSV and, to a lesser extent, VZV. It is only of limited efficacy against EBV and CMV. However, valaciclovir has been shown to lower or eliminate the presence of the Epstein–Barr virus in subjects afflicted with acute mononucleosis, leading to a significant decrease in the severity of symptoms.[12][13][14] Valaciclovir and acyclovir act by inhibiting viral DNA replication, but as of 2016 there was little evidence that they are effective against Epstein–Barr virus.[20] Acyclovir therapy does prevent viral latency, but has not proven effective at eradicating latent viruses in nerve ganglia.[19]
As of 2005, resistance to valaciclovir has not been significant. Mechanisms of resistance in HSV include deficient viral thymidine kinase and mutations to viral thymidine kinase and/or DNA polymerase that alter substrate sensitivity.[21]
It also is used for
Chemistry
Details of the synthesis of valaciclovir were first published by scientists from the
Aciclovir was esterified with a
History
Valaciclovir was patented in 1987 and came into medical use in 1995.
Society and culture
Brand names
It is marketed by
References
- ^ a b c d e f "Valtrex- valacyclovir hydrochloride tablet, film coated". DailyMed. 14 June 2021. Retrieved 22 May 2022.
- ^ a b c d e f g "Valacyclovir Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 17 March 2019.
- ^ ISBN 978-1437727029.
- ^ ISBN 9783527607495.
- hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ ISBN 9780857113382.
- ^ a b "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ a b "Valacyclovir - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- ^ ISBN 0-9757919-2-3[page needed]
- ISBN 978-3-8055-7982-7. Retrieved 1 January 2012.
- S2CID 2969472.
- ^ a b Balfour HH, Hokanson KM, Schacherer RM (December 2005). A controlled trial of valacyclovir in infectious mononucleosis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. pp. 16–19. Abstract V1392.
- ^ a b Simon MW, Deeter RG, Shahan B (March 2003). "The Effect of Valacyclovir and Prednisolone in Reducing Symptoms of EBV Illness In Children: A Double-Blind, Placebo-Controlled Study". International Pediatrics. 18 (3): 164–169 – via ResearchGate.
- ^ PMID 17369082.
- ^ a b "Herpes B Virus: Information For Healthcare Providers". U.S. Centers for Disease Control and Prevention (CDC). 31 January 2019. Retrieved 22 May 2022.
- S2CID 36915347.
- PMID 31486071.
- ^ "Valaciclovir (VCV) - USCN LIFE SCIENCE INC". www.uscnk.us. Archived from the original on 3 December 2014.
- ^ S2CID 240858022.
- PMID 27933614.
- OCLC 56903116.[page needed]
- S2CID 4652818.
- ^ EP patent 308065, Krenitsky, Thomas Anthony & Beauchamp, Lilia Marie, "Therapeutic nucleosides", published 1989-03-22, assigned to Wellcome Foundation
- S2CID 75449475.
- ^ Ahmed R (27 November 2009). "Ranbaxy Launches Generic Valtrex in U.S." The Wall Street Journal. Retrieved 16 January 2010.